Pharmaceutical company Pfizer, Inc. (NYSE: PFE) announced that it has entered a new research, development, and commercialization collaboration agreement with next-generation immunotherapy company BioNTech SE (NASDAQ: BNTX) for the development of a potential first mRNA-based vaccine to prevent shingles (herpes zoster virus, or HZV).  Shingles is a painful disease that impacts about one in three individuals in the United States during their lifetime. Shares of Pfizer rose 2% to close at $55.63 on Wednesday.  The collaboration follows the companies’ success in developing the first approved and widely-accepted mRNA vaccine to help prevent COVID-19. Markedly, this is the third partnership between Pfizer and BioNTech in the infectious diseases field.
https://www.tipranks.com/news/pfizer-biontech-ink-collaboration-deal-to-develop-mrna-based-vaccine-for-shingles?utm_source=advfn.com&utm_medium=referral